Uncertainty About Supply Chain Keeps Baxter Out Of Heparin Market
This article was originally published in The Tan Sheet
Executive Summary
Baxter International is unsure whether it will re-enter the Rx blood thinner heparin market due in part to concerns about a "complex and difficult" ingredient supply chain, according to CEO Robert Parkinson
You may also be interested in...
Heparin Fallout Likely To Impact Supplement Ingredient Testing Exemptions
The discovery of adulterated ingredients in imported prescription drugs will likely cause increased scrutiny of supply chain operations for other segments across the food and drug industries
FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down
FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills
FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down
FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills